Cargando…
The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia
Hemophilia A is a rare X-linked bleeding disorder caused by lack or dysfunction of coagulation factor VIII (FVIII). Hemophilia A is treated with replacement therapy, but frequent injections of the missing FVIII often lead to the formation of inhibitory antibodies. Patients who develop high levels of...
Autores principales: | Yatuv, Rivka, Robinson, Micah, Dayan-Tarshish, Inbal, Baru, Moshe |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939703/ https://www.ncbi.nlm.nih.gov/pubmed/20856833 |
Ejemplares similares
-
Molecular Simulations of PEGylated Biomolecules, Liposomes, and Nanoparticles for Drug Delivery Applications
por: Lee, Hwankyu
Publicado: (2020) -
Maleimide-Decorated PEGylated Mucoadhesive Liposomes
for Ocular Drug Delivery
por: Moiseev, Roman V., et al.
Publicado: (2022) -
Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs
por: Lin, Yi-Yu, et al.
Publicado: (2013) -
The availability of drug by liposomal drug delivery: Individual kinetics and tissue distribution of encapsulated and released drug in mice after administration of PEGylated liposomal prednisolone phosphate
por: Smits, Evelien A. W., et al.
Publicado: (2018) -
PEGylated liposomes: immunological responses
por: Mohamed, Marwa, et al.
Publicado: (2019)